INVAC-1

BIOLOGICAL2 trials

Sponsors

Invectys

Conditions

Leukemia, Lymphocytic, Chronic, B-CellSolid Tumors

Phase 1

INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

CompletedNCT02301754

InvectysSolid Tumors

Start: 2014-11-30End: 2018-06-01Updated: 2019-02-26

Phase 2

DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

TerminatedNCT03265717

InvectysLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2018-07-25End: 2020-06-30Updated: 2020-07-08

Related Papers

Abstract CT021: INVAC-1, an optimized telomerase DNA vaccine in patients with advanced solid tumors: Final results of first-in-human phase I study

Cancer Research2021-07-011 citations

Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-20

Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors

Annals of Oncology2018-10-01

Results of a first-in-human phase I study of INVAC-1, an optimized plasmid DNA encoding an inactive form of human telomerase reverse transcriptase (hTERT), in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-202 citations